Intellectus Partners’s Gyre Therapeutics GYRE Stock Holding History

Intellectus Partners’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9	Closed	-$1K	–	365
2018 Q3	$1K	Buy	+9	New	+$713	﹤0.01%	563

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Intellectus Partners's GYRE Position: Q3 2018 in Review

Intellectus Partners sold out of Gyre Therapeutics (GYRE) in Q3 2018, closing a stake of 9 shares — an estimated $713 sold.

Intellectus Partners first reported a position in GYRE in Q4 2016 and held it in 7 quarters. The position peaked at $61K in Q4 2016. 70 funds tracked by Wall St. Rank hold GYRE as of Q3 2018.

Intellectus Partners reported no remaining Gyre Therapeutics position as of Q3 2018 after selling out during the quarter.
Intellectus Partners sold 9 Gyre Therapeutics shares in Q3 2018, an estimated $713.
Intellectus Partners first reported a position in Gyre Therapeutics in Q4 2016 and held it in 7 quarters.
Intellectus Partners's Gyre Therapeutics position peaked at $61K in Q4 2016.
70 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2018.

Based on Intellectus Partners's 13F filing for Q3 2018, filed 15 Nov 2018.